Back

Early in-hospital initiation of dapagliflozin versus empagliflozin in acute heart failure: impact on in-hospital survival and safety

29 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Acute heart failure therapies: timing, choices, and comparative effectiveness Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Nada Benameur

Tanger University Hospital Center, Tangier (Morocco)

5 More presentations in this session

Presentation thumbnail
SGLT2 inhibitor outcomes in elderly post-MI patients with mildly reduced ejection fraction: age-stratified real-world evidence
Doctor A. Ajibade (Iowa City, US)
Abstract
Presentation thumbnail
Impact of levosimendan versus dobutamine on 30-day mortality and hospital stay in acute decompensated heart failure: a systematic review and meta-analysis
Doctor H. Amorim Parente (Rio de Janeiro, BR)
Abstract
Presentation thumbnail
From trials to treatment: real-world vericiguat initiation and residual risk in Germany
Doctor F. Kerwagen (Wuerzburg, DE)
Abstract
Presentation thumbnail
Does initiating SGLT2 inhibitors at an early stage of heart failure admission really reduce cardiovascular mortality and first rehospitalization? A meta-analysis of randomized controlled trials
Doctor E. Alupei (RO)
Abstract
Presentation thumbnail
Early catheter ablation for atrial fibrillation in acute heart failure: prognostic impact across age and ejection fraction
Doctor A. Okahara (Fukuoka, JP)
Abstract

Access the full session

Session thumbnail
Acute heart failure therapies: timing, choices, and comparative effectiveness

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Short-term effects of dapagliflozin versus canagliflozin on acute decompensated heart failure in patients with type 2 diabetes
2 September 2019
thumbnail
Congress Session
SGLT2 inhibitors in practice (part 4): initiating heart failure treatment in hospital
28 August 2022
thumbnail
Congress Presentation
Impact of early initiation of SGLT2 inhibitor on cardiovascular outcomes in diabetic patients with known atherosclerotic cardiovascular disease or risk factors: propensity score matched analysis
27 August 2021
thumbnail
Congress Presentation
Divergent electrophysiologic safety profile of dapagliflozin and empagliflozin in a whole-heart model
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources